Article No
155-10-065
SARS-CoV-2 Nucleocapsid
SARS-CoV-2 Nucleocapsid Antibody
Antibodies Primary
Specifications
| Application | ELISA, IHC, WB |
| Article No | 155-10-065 |
| Country Availability | SE, FI, DK, NO, IS, EE, LV, LT, FO, GL |
| Clone | 1C7C7 |
| Clone Type | monoclonal |
| Concentration | > 1 mg/ml |
| Conjugation | Unconjugated |
| Description | SARS-CoV-2 Nucleocapsid Antibody |
| Supplier | ProSci |
| Format | Liquid |
| Immunogen | Recombinant nucleoprotein of SARS-CoV (severe acute respiratory syndrome).The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2. |
| Isotype | IgG2a |
| Notes | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The N protein is 46 kDa and consists of two highly conserved structural domains, the N-terminal domain (NTD) and C-terminal domain (CTD), connected by a linker region. The NTD and CTD are involved in RNA binding and self-oligomerization, respectively 3, 4. The primary function of the N protein is to bind to and package the viral RNA genome into a helical ribonucleoprotein complex 5. The N protein is also involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways 6, 7. The N protein is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARS-CoV N protein 8. It is also immunogenic, and antibodies 8,9 and memory T cells 10, 11 targeting the N protein are present in the sera of convalescent COVID-19 patients, identifying the N protein as a suitable candidate for vaccine development and diagnostic assays. Diagnostic assays based on the N protein effectively detect antibodies in the sera of patients infected with SARS-CoV-2 12. The N protein also contributes to immune evasion by antagonizing antiviral RNAi 13, suggesting its potential value as a targeted therapeutic. |
| Alias Names | SARS-CoV-2 Nucleocapsid, SARS-CoV-2 Nucleoprotein, Protein N, SARS-CoV N Protein |
| Previous Article No | 155-10-065-0.1 |
| Product Type | Antibodies Primary |
| Protocol | ELISA, IHC, WB (Quality Tested by ProSci); FC (Other applications as reported in literature) |
| Purification | >95% by SDS Page |
| Shipping Information | BLUE ICE |
| Size | 0.1 mg |
| Source / Host | human |
| Species Reactivity | virus |
| Storage | Functional grade preclinical antibodies may be stored sterile as received at 2-8˚ C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80˚ C. Avoid Repeated Freeze Thaw Cycles. |
| Substrate / Buffer | This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added. |
| Product Page Updated | 2024-01-25T14:38:09.103Z |
